Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Capital Inc Broadwood currently holds 10,768,430 shares of OncoCyte Corp (OCX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Capital Inc Broadwood has been a net seller of OCX stock. They have purchased $64.0M and sold $134.4M worth of shares.
Capital Inc Broadwood's most recent insider trade was on Jan 8, 2024, when they purchased 4,042 shares at $27.11 per share.
Capital Inc Broadwood serves as Executive at OncoCyte Corp (OCX). They have executed 496 insider transactions totaling $198.4M over their tenure at the company.
Capital Inc Broadwood holds the position of Executive at OncoCyte Corp, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 19 years and currently hold a stake valued at $0.
Capital Inc Broadwood has shown a selling trading pattern, with $64.0M in total purchases and $134.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Capital Inc Broadwood was on Jun 28, 2021, when they sold $20.2M worth of STAA shares. This transaction involved 130,000 shares at $155.19 per share.
Capital Inc Broadwood currently owns 10,768,430 shares of OncoCyte Corp (OCX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Capital Inc Broadwood's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Capital Inc Broadwood has 496 Form 4 filings on record as an insider at OncoCyte Corp.
Set alerts for Capital Inc Broadwood and 40,000+ other insiders.